Compare The Pennant Group, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,038 Million (Small Cap)
35.00
NA
0.00%
0.14
10.40%
3.22
Revenue and Profits:
Net Sales:
229 Million
(Quarterly Results - Sep 2025)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.79%
0%
27.79%
6 Months
36.34%
0%
36.34%
1 Year
11.5%
0%
11.5%
2 Years
99.02%
0%
99.02%
3 Years
144.17%
0%
144.17%
4 Years
106.32%
0%
106.32%
5 Years
-45.44%
0%
-45.44%
The Pennant Group, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.12%
EBIT Growth (5y)
16.36%
EBIT to Interest (avg)
6.96
Debt to EBITDA (avg)
2.88
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
2.30
Tax Ratio
22.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.48%
ROE (avg)
9.26%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
3.36
EV to EBIT
24.80
EV to EBITDA
21.52
EV to Capital Employed
2.93
EV to Sales
1.45
PEG Ratio
0.70
Dividend Yield
NA
ROCE (Latest)
11.79%
ROE (Latest)
9.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 56 Schemes (31.63%)
Foreign Institutions
Held by 84 Foreign Institutions (21.14%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
229.00
219.50
4.33%
Operating Profit (PBDIT) excl Other Income
15.30
13.80
10.87%
Interest
1.00
1.20
-16.67%
Exceptional Items
-3.10
-1.10
-181.82%
Consolidate Net Profit
6.90
8.00
-13.75%
Operating Profit Margin (Excl OI)
58.00%
52.90%
0.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 4.33% vs 4.62% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -13.75% vs -5.88% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
695.20
544.90
27.58%
Operating Profit (PBDIT) excl Other Income
44.30
30.80
43.83%
Interest
7.00
5.90
18.64%
Exceptional Items
-0.70
-0.50
-40.00%
Consolidate Net Profit
24.30
13.90
74.82%
Operating Profit Margin (Excl OI)
54.90%
47.20%
0.77%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 27.58% vs 15.15% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 74.82% vs 93.06% in Dec 2023
About The Pennant Group, Inc. 
The Pennant Group, Inc.
Pharmaceuticals & Biotechnology
Pennant Group, Inc. is a holding company. The Company through its subsidiaries provides healthcare services to the senior population in the United States. The Company operates home health, hospice and senior living across Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. It operates through two segments: home health and hospice services and senior living services. It's home health and hospice services segment include its home health, hospice and home care businesses. It provides home health and hospice services through approximately 80 agencies. Senior living services segment includes its assisted living, independent living and memory care communities. It provides assisted living, independent living and memory care services at approximately 54 communities with 3,872 total units.
Company Coordinates 
Company Details
1675 E Riverside Dr Ste 150 , EAGLE ID : 83616-7471
Registrar Details






